Core Viewpoint - The company Valiant Bio-B (09887) has seen a significant stock increase of nearly 6%, currently trading at 62.2 HKD, with a transaction volume of 11.42 million HKD, following the announcement of its dual-specific antibody LBL-034 receiving Fast Track designation from the FDA for the treatment of relapsed/refractory multiple myeloma (RRMM) [1] Group 1 - Valiant Bio-B's LBL-034, developed using its proprietary TCE technology platform LeadsBody, has been granted Fast Track designation by the FDA [1] - This designation marks an important milestone in the international development of LBL-034, following its orphan drug designation received in October 2024 [1] - The recognition from international regulatory bodies further validates the clinical value and development strategy of LBL-034 [1] Group 2 - LBL-034 is a humanized dual-specific T-cell engager targeting GPRC5D and CD3 [1]
维立志博-B再涨近6% TCE双抗LBL-034获FDA快速通道资格认定